Loading…
Abstract 033: Identification of s Primary Renal AT 2 Receptor Defect in Spontaneously Hypertensive Rats (SHR)
Abstract only Angiotensin III (Ang III) [des-aspartyl 1 -Ang II] is the predominant endogenous agonist for angiotensin type-2 receptor (AT 2 R)-induced natriuresis in rats. Hypertensive 12 wk-old SHR lack natriuretic responses to Ang III, and renal interstitial (RI) Ang III administration induces na...
Saved in:
Published in: | Hypertension (Dallas, Tex. 1979) Tex. 1979), 2018-09, Vol.72 (Suppl_1) |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Abstract only
Angiotensin III (Ang III) [des-aspartyl
1
-Ang II] is the predominant endogenous agonist for angiotensin type-2 receptor (AT
2
R)-induced natriuresis in rats. Hypertensive 12 wk-old SHR lack natriuretic responses to Ang III, and renal interstitial (RI) Ang III administration induces natriuresis in 4 wk-old Wistar-Kyoto rats (WKY), but not in 4 wk-old pre-hypertensive SHR. The defect in natriuresis could be explained by the concurrent observation that in WKY, but not SHR, Ang III induced AT
2
R translocation to renal proximal tubule apical plasma membranes and internalization/inactivation of Na
+
-transporters Na
+
- H
+
exchanger-3 (NHE-3) and Na
+
/K
+
ATPase (NKA). These findings suggest an Ang III/AT
2
R signaling defect in pre-hypertensive SHR. The present study sought to determine the cause of the defect: (1) accelerated intrarenal Ang III metabolism or (2) a primary AT
2
R (or post-receptor) signaling defect. Selective AT
2
R agonist Compound-21 (C-21) was infused interstitially [20, 40 and 60 ng/kg/min, each dose for 30 min] into experimental (left) kidneys of 4 wk-old WKY and SHR (N=7) pretreated for 24h with systemic infusion of Ang type-1 receptor (AT
1
R) antagonist candesartan (0.01 mg/kg/min by osmotic minipump); vehicle was infused into control (right) kidneys. Pre-infusion urinary Na
+
excretion (U
Na
V) was 0.022 ± 0.004 μmol/min in WKY and 0.024 ± 0.005 μmol/min in SHR (P=NS). In WKY, C-21 dose-dependently increased U
Na
V from 0.022 ± 0.004 to 0.058 ± 0.017, 0.078 ± 0.014 and 0.079 ± 0.079 μmol/min (P=0.01 from pre-infusion and time control kidneys). In contrast, SHR did not increase U
Na
V in response to C-21 [highest U
Na
V 0.033 ± 0.007 μmol/min (P=NS from pre-infusion and time control kidneys)]. Mean arterial pressure (MAP) was 64.6 ± 1.80 mmHg in WKY and 76.4 ± 2.2 mmHg (P |
---|---|
ISSN: | 0194-911X 1524-4563 |
DOI: | 10.1161/hyp.72.suppl_1.033 |